224785-90-4 Usage
Description
Vardenafil hydrochloride trihydrate, also known by the brand name Levitra, is a potent PDE5 inhibitor used for the oral treatment of male erectile dysfunction. It shares significant structural similarity with sildenafil (Viagra), another PDE5 inhibitor. Vardenafil is synthesized through a three-step process and exhibits a higher potency of PDE5 inhibition compared to sildenafil. It is typically administered in single doses of 10 and 20 mg, with a rapid time to reach maximum plasma concentration and a half-life of 4-5 hours.
Uses
Used in Erectile Dysfunction Treatment:
Vardenafil hydrochloride trihydrate is used as a PDE5 inhibitor for the treatment of male erectile dysfunction. It works by enhancing the effects of nitric oxide, which relaxes the blood vessels and allows for increased blood flow to the penis, resulting in an erection when sexually stimulated.
Used in Cosmetics and Personal Care Products:
Vardenafil hydrochloride trihydrate is also utilized in the cosmetics and personal care industry, although the specific application reasons are not detailed in the provided materials. It may be used for its vasodilatory properties or other potential benefits related to skin health and appearance.
Originator
Bayer AG (Germany)
Flammability and Explosibility
Nonflammable
Clinical Use
Treatment of erectile dysfunction
Drug interactions
Potentially hazardous interactions with other drugs
Alpha-blockers: enhanced hypotensive effect - avoid
for 6 hours after alpha-blockers (max dose 5 mg).
Antifungals: concentration increased by
ketoconazole, and itraconazole - avoid concomitant
use.
Antivirals: concentration increased by fosamprenavir,
indinavir and ritonavir- avoid with indinavir and
ritonavir; increased risk of ventricular arrhythmias
with saquinavir - avoid; avoid with telaprevir, use
tipranavir with caution.
Cobicistat: concentration of vardenafil possibly
increased - reduce dose of vardenafil.
Grapefruit juice: concentration possibly increased -
avoid concomitant use.
Nicorandil: possibly enhanced hypotensive effect -
avoid concomitant use.
Nitrates: possibly enhanced hypotensive effect -
avoid concomitant use.
Riociguat: enhanced hypotensive effect - avoid
concomitant use.
Metabolism
Vardenafil is metabolised in the liver primarily by
cytochrome P450 isoenzymes CYP3A4 (the major route)
as well as CYP3A5 and CYP2C isoforms. The major
metabolite produced by desethylation of vardenafil also
has some activity.
Vardenafil is excreted as metabolites mainly in the faeces
(91 to 95%), and to a lesser extent in the urine.
Check Digit Verification of cas no
The CAS Registry Mumber 224785-90-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,4,7,8 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 224785-90:
(8*2)+(7*2)+(6*4)+(5*7)+(4*8)+(3*5)+(2*9)+(1*0)=154
154 % 10 = 4
So 224785-90-4 is a valid CAS Registry Number.
InChI:InChI=1/C23H32N6O4S.ClH.3H2O/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);1H;3*1H2
224785-90-4Relevant articles and documents
A METHOD FOR THE PREPARATION AND ISOLATION OF SALTS OF VARDENAFIL WITH ACIDS
-
Page/Page column 17, (2013/06/06)
The subject of this invention provides a method of preparation and isolation of water-insoluble or partially soluble salts of vardenafil of formula 1, in particular its salts with acids in the ratio of components 1 : 1 (of formula 2a, HA stands for any acid), and of crystalline hydrates of said salts. These solid forms, in particular crystalline vardenafil hydrochloride trihydrate of formula 4, can be directly, without additional purification, used in preparation of a medicine for the therapy of erectile dysfunction. The present solution is based on using water as a suitable medium both for obtaining of extracts of the water-soluble forms of vardenafil, and for isolation and subsequent crystallization of solid water-insoluble or partially soluble salts of vardenafil with acids (1 : 1). Crystallization of the isolated salts takes place after adjustment of pH of the aqueous solutions by means of aqueous solutions of bases or acids, wherein no organic solvent or a mixture thereof with water is needed for the crystallization. The method according to this invention reduces costs for organic solvents, increases efficiency of isolation of the vardenafil salts with acids, and facilitates preparation of poorly stable hydrates of these salts.
N-BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF
-
, (2011/08/08)
Disclosed are N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide (which is represented by formula III), its preparation method, intermediates during preparation procedure, preparation method for such intermediates and a method for preparing vardenafil from the compound. In the method for preparing vardenafil, a chloro-sulfonation reaction carries out in the early stage of the preparation procedure.
PROCESSES FOR THE PREPARATION OF VARDENAFIL
-
, (2011/02/24)
The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates.
